Cerebral glucose utilization (CGU)

Cerebral glucose utilization (CGU) represents the rate of glucose consumption by the brain, serving as the primary energy source for maintaining neuronal and glial homeostasis (Hoyer, S., 1992, J Neural Transm). Because the brain has limited glycogen storage, it relies on the transport of glucose across the blood-brain barrier via GLUT1 and into neurons via GLUT3 (Mergenthaler et al., 2013, Trends Neurosci). This metabolic process is essential for ATP production, which fuels the sodium-potassium pump and supports synaptic transmission. In clinical settings, CGU is a vital biomarker of regional brain activity, typically measured using 18F-FDG Positron Emission Tomography (PET) (Mosconi, L., 2013, J Alzheimers Dis). Reductions in CGU, known as hypometabolism, are strongly associated with neurodegenerative diseases like Alzheimer's and Parkinson's, often preceding structural atrophy (Cunnane et al., 2011, Front Aging Neurosci). Conversely, focal hypermetabolism is a defining feature of the ictal state in epilepsy. Emerging therapeutic approaches, including the use of GLP-1 receptor agonists and insulin sensitizers, aim to restore CGU to treat cognitive decline (Gejl et al., 2016, Sci Rep).

Other names

Cerebral metabolic rate of glucoseCMRglcBrain glucose metabolismRegional cerebral glucose utilizationrCGU

Cerebral glucose utilization is a physiological process rather than a discrete molecular target; drugs modulate this rate by acting on glucose transporters (e.g., GLUT1, GLUT3), activating insulin or GLP-1 receptors to improve metabolic efficiency, or altering neuronal demand through neurotransmitter modulation (PubMed, NIH).